




# Half Year 2025 Results

Webstream Conference | July 22, 2025



# Agenda

---

## Half-year 2025 Business Review

Volker Cwielong, CEO

---

## Half-year 2025 Financial Review

Dr. Judith van Walsum, CFO

---

## Market Expectations and Outlook

Volker Cwielong, CEO

---

## Q&A

---

A close-up, low-angle shot of a 3D printer's nozzle, which is a dark, conical shape, extruding a fine stream of red material onto a flat surface. The material being printed has a fine, grid-like texture. The background is blurred, showing more of the red printed part and the printer's structure.

# Half Year 2025 Business Review

Volker Cwielong, CEO

# Datwyler gained important momentum in first half of 2025 with growth in Healthcare and improved EBIT margin



- **Net revenues** slightly dipped to **CHF 563.0m** (-1.7% vs. PY) primarily due to large FX impacts, currency-adjusted growth of 1.3%
- **Significant momentum in Healthcare**, solid growth in segment Food&Beverage, softened demand in Automotive and Industry
- **EBIT margin increased** to 12.2% (+ 0.4 pp vs. PY), primarily driven by volume recovery and product mix in Healthcare
- **Operational improvements** and cost adjustment across all segments, limited direct impacts of tariff conflicts successfully mitigated


# New business wins prioritize innovation and high-value offerings, transformation program ForwardNow is on track



- Attractive **new project wins** in both divisions with strong focus on innovative, **high-value products** with superior customer value
- **Flawless production ramp-up** for GLP-1 and enhanced traction for NeoFlex products in Healthcare, new co-engineered programs in Industrial with large share in high-voltage applications
- Four **ForwardNow** action areas are being rapidly advanced through twenty targeted initiatives and coordinated by dedicated transformation team
- **Early efficiency gains** from initiatives are already visible, putting 2025 program targets well within reach



# Healthcare market with strong momentum, softened demand in Automotive and Industry segments, continued growth in F&B





# Half Year 2025 Financial Review

Dr. Judith van Walsum, CFO

# Datwyler Group: half year net revenue at CHF 563m, currency adjusted +1.3%, EBIT margin improved by 0.4pp to 12.2%

## Profit and Loss Statement

	in CHF M	HY2025 ACT	HY2024 ACT	Δ in %
1	<b>Net revenue</b>	<b>563.0</b>	<b>572.5</b>	-1.7%
	Costs of goods sold	(432.8)	(444.9)	-2.7%
2	<b>Gross profit</b>	<b>130.2</b>	<b>127.6</b>	<b>2.0%</b>
	Operating Expenses	(61.3)	(60.1)	2.0%
3	<b>EBIT</b>	<b>68.9</b>	<b>67.5</b>	<b>2.1%</b>
4	Net finance result	(12.7)	(12.4)	2.4%
	<b>Earnings before tax (EBT)</b>	<b>56.2</b>	<b>55.1</b>	<b>2.0%</b>
5	Income tax expenses	(18.3)	(16.5)	10.9%
6	<b>Net result</b>	<b>37.9</b>	<b>38.6</b>	<b>-1.8%</b>
	<i>in % of net revenue</i>			<b>Δ in pp</b>
	Gross profit	23.1%	22.3%	0.8pp
	EBIT-margin	12.2%	11.8%	0.4pp
	<i>in CHF</i>			<b>Δ in %</b>
	Net result per bearer share	2.23	2.27	-1.8%


## Key highlights

- 1 Currency adjusted net revenue growth driven by Healthcare and F&B  
Challenging market conditions notably in Automotive and Industry
- 2 Gross profit margin improvement due to favorable product mix in Healthcare and tight cost control
- 3 Reported EBIT at CHF 68.9M, 2.1% above PY
- 4 Turbulent Forex development led to slightly higher net finance result
- 5 Higher income tax expenses, also due to non-recognition of DTAs
- 6 Net result at 6.7% of net revenues as in prior year



# Currency-adjusted growth driven by Healthcare and F&B, reported revenue unfavorably impacted by FX headwinds

## Revenue Bridge Half Year 2025 in CHF M




## Key highlights

- Top line significantly impacted by negative currency effect due to the strong Swiss Franc: CHF 16.7M FX (-2.9%). Changes in interdivisional sales at CHF 1.5M
- Healthcare's higher volumes and improved product mix, as well as F&B continued growth at double digit EBIT margin offset decline in T&E

# Higher volumes and better product mix in Healthcare lead to growth, improved gross profit margin and increased EBIT

## EBIT Bridge Half Year 2025 in CHF M




## Key highlights

- Reported EBIT at 12.2% of net revenues (+0.4pp vs PY) despite slow start to the year and weak demand in Transport & Electronics
- Sales grew faster than COGS due to improved product mix in Healthcare, resulting in higher profit contribution
- COGS growth kept in check thanks to lower material cost and reduced expenses
- Slight increase in Opex in absolute terms (inflation, build up capabilities), yet staying stable as % of revenues


(1) Net other Operating Expenses includes Research and Development (R&D), Marketing and Selling (M&S) and General and Administrative (G&A).

# Division Healthcare: Strong momentum after slow start in Q1, solid growth and improved product mix in Q2


**Revenue** in CHF M




**EBIT** in CHF M



**Revenue split by regions** in %



**EBIT margin** in %



## Key highlights


- Currency-adjusted revenues at +5.8% above PY. Org change CHF +13.4M
- The GP margin increased from 22.7% in the PY to 24.8% in the current year, reflecting better product mix, higher capacity utilization and strict cost control
- Higher Opex reflecting wage inflation & build up capabilities, partially offset by income from services
- Several transformation projects ongoing to streamline operations and improve productivity

# Division Industrial: Solid performance despite challenging market conditions, continued growth in Food & Beverage


## Revenue in CHF M




## EBIT in CHF M



## Revenue split by regions in %



## EBIT margin in %




## Key highlights


- Currency-adjusted revenue dropped by -1.4%. F&B with solid growth. Weaker demand particularly in automotive
- Despite headwinds, the gross profit margin remained stable at 21.7%
- Stringent cost control and efficiency gains enabled Industrial Division to keep a solid profit margin (8.7%)
- Strong focus on several initiatives transformation projects notably on foot print consolidation and SKU streamlining

# Net interest expenses reduced due to debt repayments, active hedging limited FX volatility

## Total interest and finance expenses in CHF M



## Income tax expense in CHF M



## Key highlights


- Interest expenses (net) reduced to CHF 4.0M, PY CHF 4.7M, due to debt repayments
- Net CHF 8.3M fair value losses on forward contracts of CHF 36.5M, offset by CHF 28.2M gains on hedging derivatives
- The tax expense is higher because of non-recognition of DTAs in selected sites, tax provisions and non-recoverable withholding taxes on dividends and intercompany charges





# Net working capital improving as a result of cash improvement initiatives in execution


## Net Working Capital in CHF M



## Key highlights

- Net working capital improving; cash conversion cycle from 128 to 116 days YoY
- Trade Accounts Receivables increased in line with higher sales in Healthcare. Cash collection optimization project running
- Trade Accounts Payables have seen the most improvements in recent months, due to higher effectiveness of Procurement as a result of the ongoing transformation
- Inventory has consistently decreased in the past months, and we see further potential

# Continued repayment of loans leads to lower net debt and improved leverage vs. PY



## Key highlights

- Net debt improved materially vs PY
- All remaining third-party debt paid off in HY2 2024; further repayments of PEMA loans, including 25M in HY1 2025
- Net debt / adjusted LTM EBITDA at 2.2, improved vs HY1 2024, even vs adjusted year-end 2024

# Free Cash Flow remained strong in absolute terms, allowing for continued reduction of liabilities to anchor shareholder

## Free Cash Flow

in CHF M	HY2025 ACT	HY2024 ACT
<b>Net cash from operating activities</b>	<b>90.3</b>	<b>86.3</b>
Net cash used in investing activities	(25.3)	(20.5)
<b>Free cash flow (FCF)</b>	<b>65.0</b>	<b>65.8</b>
Net cash used by financing activities	(81.0)	(91.4)

## Key highlights

- Solid operating cash flow, improved compared to PY by CHF 4.0M. Strong sales, notably in Q2, in Healthcare and Food & Beverages leading to higher receivables
- Capital expenditures in HY1 of CHF 25.3M higher than in the PY but still at relatively low levels (~4.5% of sales)
- Financing activities include the dividend payment of CHF 54.4M and debt repayment Pema loan CHF 25.0M in 2025





# 2025 Market Expectations and Outlook

Volker Cwielong, CEO

# Outlook 2025: We anticipate steady recovery in Healthcare and remaining uncertainty for Automotive in Europe and Americas

## Healthcare



### Market Expectations for HY2 2025

- With a strong order book, we expect the recovery to continue and destocking effect to fully phase out
- Return to long-term growth trend in the higher single-digit percentage range for injectables projected

## Automotive





### Datwyler Positioning

- Datwyler is ready to scale volumes with its state-of-the-art manufacturing sites
  - Intensified collaboration with pharma companies and system integrators
  - Successful production ramp-up for GLP-1 applications and NeoFlex products
- 
- Continuous portfolio streamlining and effective cost measures in place
  - Strong position and momentum for new business wins in China
  - Attractive product portfolio and local-for-local production set-up



# Outlook 2025: Industry markets expected to recover gradually, Food & Beverage to continue on growth path

	Market Expectations for HY2 2025	Datwyler Positioning
<b>Industries</b> 	<ul style="list-style-type: none"><li>▪ Demand likely to be influenced by cautious sentiment, target sectors are expected to rebound i.e. connectivity</li><li>▪ Policy driven recovery in the US energy market may be delayed by oil price development</li></ul>	<ul style="list-style-type: none"><li>▪ Recent project wins in outperforming segments will enhance strong position</li><li>▪ Proprietary certified elastomer compounds and optimized manufacturing capabilities</li><li>▪ Strong base to benefit from the next US energy growth cycle</li></ul>
<b>F&amp;B</b> 	<ul style="list-style-type: none"><li>▪ Continuous growth in the end market for single-serve coffee capsules anticipated with aluminum as material of choice - supported by EU packaging regulation</li></ul>	<ul style="list-style-type: none"><li>▪ Continuous ramp up of additional capacity based on our supply agreements</li><li>▪ Specialized on processing of aluminium with a recycling ratio of higher than 90%</li></ul>

# The ForwardNow transformation program was successfully rolled out with 20+ initiatives across four action areas



## PRODUCTION NETWORK

Optimization for faster, more competitive market access



## COMMERCIAL EXCELLENCE

Positioning as preferred development partner to capture more value



## PRODUCT PORTFOLIO

Streamlining for clarity, simplicity, and stronger value contribution



## TARGET OPERATING MODEL

Implementing a lean structure and global standards to drive agility, efficiency and scalable growth

**3 years**

Project period from 2025-2027

**52.0 mCHF**

Cumulative positive earnings effects within the project period

**24.0 mCHF**

Annual earnings improvement after completion of all project initiatives

One-time negative effect of 37.9 mCHF in the reporting year 2024

# With multiple ForwardNow initiatives in progress, we are on track to meet our 2025 contribution goals

## Corporate functions reduced from five to four

- Group Executive Committee consists of Chief Executive Officer, Division Healthcare Division Industrial, Finance and Technology and Innovation
- Sustainability and Operational Excellence integrated into existing functions from June



## Organizational synergies in the Industrial division

- Business Units Connectors and Mobility have been merged to Transportation & Electronics
- Modular organization model to accelerate time to market and leverage important synergies along the entire value chain





## Streamlined production network and product portfolio


- Products from Vandalia site will be relocated to two Datwyler U.S. production sites, Vandalia to close by September 2025
- Industrial division has made solid progress in sharpening its product portfolio, effectively reducing overall complexity



# Mid-term targets under normal operating market conditions



**Q&A**







# Financial Calendar 2025

## Company events

28 Aug.	Roadshow Zurich
2 Sept.	Roadshow London
3 Sept.	Roadshow Frankfurt
4 Sept.	Roadshow Geneva
19 Nov.	Capital Market Day

## Investor conferences

23 Sept.	UBS, virtual
5-7 Nov.	ZKB, Zurich



### **Disclaimer**

This presentation contains forward-looking statements that reflect the Group's current expectations regarding market conditions and future events and are therefore subject to a number of risks, uncertainties and assumptions. Unanticipated events could cause actual results to differ from those predicted and from the information contained in this presentation. All forward-looking statements in this presentation are qualified in their entirety by the foregoing.

### **Dätwyler Holding Inc.**

Gotthardstrasse 31, 6460 Altdorf  
T +41 41 875 11 00, F + 41 41 875 12 05  
[info@datwyler.com](mailto:info@datwyler.com), [www.datwyler.com](http://www.datwyler.com)